Show simple item record

dc.contributor.author Pálóczi, János
dc.contributor.author Varga, Zoltán V
dc.contributor.author Apáti, Ágota
dc.contributor.author Szebényi, Kornélia
dc.contributor.author Sarkadi, Balázs
dc.contributor.author Rosalinda, Madonna
dc.contributor.author Raffaele, De Caterina
dc.contributor.author Csont, Tamás Bálint
dc.contributor.author Thomas, Eschenhagen
dc.contributor.author Ferdinandy, Péter
dc.contributor.author Görbe, Anikó
dc.date.accessioned 2016-09-13T10:01:21Z
dc.date.available 2016-09-13T10:01:21Z
dc.date.issued 2016
dc.identifier 84976536872
dc.identifier.citation pagination=4298945; journalVolume=2016; journalTitle=OXIDATIVE MEDICINE AND CELLULAR LONGEVITY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3662
dc.identifier.uri doi:10.1155/2016/4298945
dc.description.abstract Background and Aims. Human embryonic stem cell- (hESC-) derived cardiomyocytes are one of the useful screening platforms of potential cardiocytoprotective molecules. However, little is known about the behavior of these cardiomyocytes in simulated ischemia/reperfusion conditions. In this study, we have tested the cytoprotective effect of an NO donor and the brain type natriuretic peptide (BNP) in a screening platform based first on differentiated embryonic bodies (EBs, 6 + 4 days) and then on more differentiated cardiomyocytes (6 + 24 days), both derived from hESCs. Methods. Both types of hESC-derived cells were exposed to 150 min simulated ischemia, followed by 120 min reperfusion. Cell viability was assessed by propidium iodide staining. The following treatments were applied during simulated ischemia in differentiated EBs: the NO-donor S-nitroso-N-acetylpenicillamine (SNAP) (10(-7), 10(-6), and 10(-5) M), BNP (10(-9), 10(-8), and 10(-7) M), and the nonspecific NO synthase inhibitor Nomega-nitro-L-arginine (L-NNA, 10(-5) M). Results. SNAP (10(-6), 10(-5) M) significantly attenuated cell death in differentiated EBs. However, simulated ischemia/reperfusion-induced cell death was not affected by BNP or by L-NNA. In separate experiments, SNAP (10(-6) M) also protected hESC-derived cardiomyocytes. Conclusions. We conclude that SNAP, but not BNP, protects differentiated EBs or cardiomyocytes derived from hESCs against simulated ischemia/reperfusion injury. The present screening platform is a useful tool for discovery of cardiocytoprotective molecules and their cellular mechanisms.
dc.relation.ispartof urn:issn:1942-0900
dc.title Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury
dc.type Journal Article
dc.date.updated 2016-09-12T08:43:54Z
dc.language.rfc3066 en
dc.identifier.mtmt 3092606
dc.identifier.wos 000378762600001
dc.identifier.pubmed 27403231
dc.contributor.department SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote FELTÖLTŐ: Sonnevend Kinga - sonnevend.kinga@med.semmelweis-univ.hu


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account